Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects

被引：0
|
作者：
Nakov, Roumen
Gattu, Sreekanth
Wang, Jessie
Velinova, Maria
Skerjanec, Andrej
机构：
[1] Hexal AG, Holzkirchen, Germany
[2] Sandoz Inc, Princeton, NJ USA
[3] PRA Hlth Sci, Groningen, Netherlands
[4] Sandoz AG, Basel, Switzerland
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-10
引用
下载
收藏
页数：1
相关论文
共 46 条
  • [1] Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects
    Nakov, Roumen
    Gattu, Sreekanth
    Wang, Jessie
    Velinova, Maria
    Schaffar, Gregor
    Skerjanec, Andrej
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (12) : 2790 - 2801
  • [2] LA-EP2006: A Pegfilgrastim Biosimilar
    Hoy, Sheridan M.
    BIODRUGS, 2019, 33 (02) : 229 - 232
  • [3] LA-EP2006: A Pegfilgrastim Biosimilar
    Sheridan M. Hoy
    BioDrugs, 2019, 33 : 229 - 232
  • [4] Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
    Harbeck, Nadia
    Lipatov, Oleg
    Frolova, Mona
    Udovitsa, Dmitry
    Topuzov, Eldar
    Ganea-Motan, Doina Elena
    Nakov, Roumen
    Singh, Pritibha
    Rudy, Anita
    Blackwell, Kimberly
    FUTURE ONCOLOGY, 2016, 12 (11) : 1359 - 1367
  • [5] Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials
    Harbeck, Nadia
    Gascon, Pere
    Jones, Clyde M.
    Nixon, Allen
    Krendyukov, Andriy
    Nakov, Roumen
    Li, Yuhan
    Blackwell, Kimberly
    FUTURE ONCOLOGY, 2017, 13 (16) : 1385 - 1393
  • [6] A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim
    Brokx, Stephen
    Scrocchi, Louise
    Shah, Nirmesh
    Dowd, Jason
    BIOLOGICALS, 2017, 48 : 28 - 38
  • [7] Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg, a pegfilgrastim biosimilar in healthy subjects
    Roth, Karsten
    Lehnick, Dirk
    Wessels, Hendrik
    Hoefler, Josef
    Gastl, Barbara
    Jankowsky, Ruediger
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (05):
  • [8] Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial
    Lickliter, Jason
    Kanceva, Radmila
    Vincent, Emmanuelle
    Schueler, Armin
    Harrison-Moench, Eleanor
    Yue, Corinne Seng
    Stahl, Michael
    Ullmann, Martin
    Ghori, Vishal
    Griffin, Paul
    CLINICAL THERAPEUTICS, 2020, 42 (08) : 1508 - +
  • [9] A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)
    Agarwala, Sanjiv S.
    Nagl, Ulrich
    Guo, Xinghua
    Bellon, Anne
    Heyn, Jens
    Dimova-Dobreva, Miryana
    Shen, Yu-Ming
    Schaffar, Gregor
    Humphrey, Martin
    Mathieson, Nicola
    Koptelova, Natalia
    Gattu, Sreekanth
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (06) : 999 - 1009
  • [10] Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer receiving myelotoxic chemotherapy: Pooled subgroup analysis of two randomized trials
    Harbeck, N.
    Gascon, P.
    Jones, C. M.
    Nixon, A.
    Krendyukov, A.
    Nakov, R.
    Mo, M.
    Blackwell, K. L.
    ANNALS OF ONCOLOGY, 2016, 27
12345